Clinical trials located in

Mainz

Mainz city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Mainz, the capital of Rhineland-Palatinate, Germany, boasts a rich history dating back to Roman times. It is the birthplace of the printing press, invented by Johannes Gutenberg in the 15th century. The city is renowned for its well-preserved old town, the magnificent Mainz Cathedral, and the annual Carnival celebrations. Mainz is also a hub for wine production, situated in the heart of the Rhine wine region, making it a key player in Germany’s wine culture. The Mainz Sand Dunes, a unique natural habitat within the city, add to its diverse landscape.

  • CT-EU-00117689

    Study ANV419 as monotherapy or in combination with pembrolizumab and ipilimumab in patients with metastatic melanoma

    The aim of this study is to test a new drug called ANV419. It will be given alone or in combination with other approved cancer medicines such as pembrolizumab or ipilimumab. The main goal is to see how well ANV419 works and whether it is safe for people with advanced cutaneous melanoma, which is a type of skin cancer that has spread or cannot be surgically removed.

    The trial is currently open to adult patients who have already been treated with drugs that target PD-1 or PD-L1 proteins, but whose cancer has continued to progress. The study will have different parts. First, doctors will find the right dose of ANV419 to use alone or in combination with other treatments. They will then check how many patients respond to treatment, which means their tumors shrink or stop spreading.

    • ANV419
    • Ipilimumab
    • Pembrolizumab
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • To evaluate the effectiveness of nivolumab used alone and in combination with HBI-8000 in the treatment of unresectable or metastatic melanoma

    This is a study comparing two treatment options for patients with melanoma that cannot be surgically removed or has spread to other parts of the body. One treatment option is an investigational drug called Tucidinostat (HBI-8000) taken by mouth twice a week in combination with an approved drug called nivolumab given by intravenous infusion. Another option is a placebo taken orally twice a week, also in combination with nivolumab given by intravenous infusion.

    The primary goal of the study is to determine whether the combination of HBI-8000 and nivolumab is more effective than nivolumab alone in shrinking the tumor or preventing further tumor progression. The study will also assess the safety of the treatment combinations.

    Patients enrolled in the main study will be randomly assigned to receive either the HBI-8000 combination or a placebo combination. Treatment will continue for up to 2 years or until the cancer progresses, side effects worsen or the patient decides to withdraw from the study. The study will last up to 4 years and will include regular monitoring and follow-up visits.

    • Placebo
    • Tudicdinostat/HBI-8000
  • Study of KRT-232 Combined with Ruxolitinib for Myelofibrosis Patients

    This here clinical trial is looking at a new drug called KRT-232 that’s taken by mouth. The study aims to see if combining KRT-232 with the existing drug ruxolitinib can help folks with myelofibrosis who ain’t responding well enough to just taking ruxolitinib alone.

    The main goal in the first part of the study is to find the right dose of KRT-232 to use when combined with ruxolitinib. They’ll be looking closely at any side effects to make sure the dose is safe. In the second part, they’ll check if the combination of the two drugs can shrink the size of the spleen by at least 35% after 6 months of treatment.

    • KRT-232
    • Ruxolitinib
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    • povorcitinib
    • ICS-LABA
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Exploring a new treatment for liver disease in a study

    This is a clinical trial that’s aiming to find the best dose of ZED1227 for treating liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The trial involves testing three different daily doses of ZED1227 compared to a placebo. The doses are 20, 50, and 100 mg. It’s a double-blind study, which means that neither the patients nor the investigators know who’s getting the actual drug and who’s getting a placebo. The main goal is to observe the relative change in serum levels of PRO-C3, a fibrosis marker produced by the liver cells. The eligibility age range for participation is 18 to 75 years old.

    • ZED1227
  • Examining repotrectinib vs crizotinib in advanced lung cancer treatment

    This trial is named TRIDENT-3, it’s for people who have a particular type of lung cancer that has spread beyond the lungs (advanced or metastatic). The lung cancer for this study is called ‘Non-Small Cell Lung Cancer’ (NSCLC) and it’s positive for an important part of the cells called ‘ROS1.’ The trial will compare two medicines: repotrectinib and crizotinib. People participating in the trial have not been treated with a group of drugs called ‘Tyrosine Kinase Inhibitors’ (TKIs) before. The main goal of this study is to see how effective and safe these two drugs are for these patients.

    • Repotrectinib
    • Crizotinib
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    • Tanimilast/CHF6001
    • Roflumilast
  • CT-EU-00057401

    Testing new pressure microcatheter vs traditional pressure wire in heart diseases

    The clinical trial is a research study about two devices that doctors use to measure the severity of a person’s heart problem: a pressure microcatheter and a pressure wire. The new device, a pressure microcatheter, is easier to use and simplifiles pullback maneuvers compared to the pressure wire. The study is done with patients with stable coronary artery disease or stabilised non-ST elevation acute coronary syndrome (ACS) with epicardial stenosis considered for PCI. The goal is to see if using the pressure microcatheter is as good as using the pressure wire. Doctors will use these devices to guide the treatment and improve the heart’s blood flow. The patient will be monitored in the hospital for a year and then checked yearly for five years. The researchers will be evaluating several things including the patient’s health outcomes, the cost and time of the procedure, and the effectiveness of the devices.

  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Understanding trastuzumab deruxtecan treatment for advanced lung cancer

    This study is testing a new lung cancer treatment, Trastuzumab Deruxtecan, to see if it’s effective and safe for patients with a certain type of advanced lung cancer (Non-Small Cell Lung Cancer with HER2 mutations). Patients in the study either receive this new treatment or standard care (cisplatin or carboplatin + pembrolizumab + pemetrexed). The main goal is to see if the new treatment helps patients live longer without their cancer getting worse and to monitor any side effects.

    • Trastuzumab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
  • Study of the combination of semaglutide and empagliflozin in patients with diabetes and non-alcoholic steatohepatitis

    This study is for people with type 2 diabetes who have a liver condition called non-alcoholic steatohepatitis (NASH). Researchers are testing new drug combinations to see if they can treat NASH in diabetic patients. They’re looking at a combo of semaglutide and empagliflozin—medicines that help control blood sugar—and comparing it to empagliflozin alone and a placebo. The main goal is to see if these treatments can improve liver health without harmful side effects. This study is significant because right now, there are no specific drugs approved to treat NASH in those with diabetes​.

    • Empagliflozin
    • Semaglutide
  • Exploring new cancer treatment for small cell lung cancer and neuroendocrine neoplasms

    The DAREON™-5 study is looking at how different amounts of a cancer drug called BI 764532 can help people with a specific type of lung cancer called small cell lung cancer, as well as other euroendocrine neoplasms. The goal is to find the right dose of BI 764532, which can be manageable for patients when taken by itself. BI 764532 is a special type of molecule that could potentially boost the body’s immune system to fight cancer. The individuals participating in the study will receive the drug through a vein and the treatment’s effectiveness will be monitored regularly until the end of the study.

    • BI 764532- new potential medication for small cell lung cancer and neuroendocrine carcinomas

See more clinical trials in other cities in Germany:

.